PZ99 thanks for your good points highlighted.
I've seen some broker reports that still refer to our original Prospectus in terms of original areas where we had patents in place. This has now been updated (see pic below) but I'm not sure about the Bene supply rights. I can assume that if we are the only ones that have patents for the treatment of BMEL in OA for example in certain areas such as Europe and US, Bene wouldn't supply to any competitors for treatment of the same patented conditions and any generics would have to undergo bio-equivalance which would involve separate trials. Please correct me if I'm wrong though. The report by Richard Moreland does go into a fair bit of detail but doesnt mention about the Bene rights and what areas it may relate to specifically.
We certainly need to know if the Bene supply contract has been expanded for other areas of the world, a good question perhaps at the next AGM or before.
- Forums
- ASX - By Stock
- research reports and media
PZ99 thanks for your good points highlighted.I've seen some...
-
- There are more pages in this discussion • 3,932 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M |
Open | High | Low | Value | Volume |
20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 387930 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 65468 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 384246 | 0.190 |
3 | 57000 | 0.185 |
8 | 194873 | 0.180 |
6 | 140904 | 0.175 |
7 | 595605 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 65468 | 2 |
0.210 | 25992 | 3 |
0.215 | 30000 | 1 |
0.220 | 27066 | 4 |
0.225 | 21604 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |